MSK-LX40 Small Cell Lung Cancer PDX Model

MSK-LX40

MSK-LX40 Small Cell Lung Cancer PDX Model

MSK-LX40
Share
Share

Sex: Male

Histology: Small cell lung cancer

Key Mutations: TP53 H179R, RB1 S567*, NOTCH1 P2Rfs*31,

MYCL Amplified

Molecular Characteristics: MSK-IMPACT, whole exome sequencing

Matched Normal: Yes

Treatment: LDE225 + cisplatin + etoposide

Site: Lung

Paired: Yes

Comments: Chemosensitive relapse

Licensing Information: Corporations and other for-profit entities may nonexclusively license Memorial Sloan Kettering’s tangible materials for research or commercial purposes. For more information, please contact [email protected].

Stage of Development

Ready to use

Indications